Both GLP-1RAs and SGLT-2is resulted in significant weight loss (at least 5%), improved HbA1c levels, and reduced blood pressure compared to placebo. Semaglutide 2.4mg showed the greatest efficacy in weight loss and glycemic control.
Patients using SGLT2 inhibitors showed a 44% reduction in all-cause mortality, a 50% reduction in severe renal disease, and a 25% reduction in cardiovascular composite outcomes, particularly driven by a 49% reduction in ischaemic stroke risk.
SGLT2i therapy was associated with a 51% lower risk of new-onset syncope, 65% lower risk of cardiovascular mortality, and 70% lower risk of all-cause mortality compared to DPP4i users.
Expected positive outcomes include improved glucose time-in-range, reduced HbA1c levels, and enhanced overall diabetes management among Ugandan youth with T1D.
The HIIT program resulted in a 30-40% increase in insulin-stimulated GDR, 8-15% increases in VOmax, decreased fat mass, and increased lean body mass. There was also a clinically relevant decrease in HbA1c levels in men with type 2 diabetes.
Identification of medications that can help manage blood glucose levels more effectively in hospitalized patients, potentially improving patient safety and glycemic control.
The study found that women using diet plus metformin had significantly higher mean glucose levels and greater variability in glucose levels compared to those using diet alone. Additionally, higher protein intake was associated with lower mean glucose levels and total area under the curve (AUC) for glucose.
HIIT showed significant improvements in cardiorespiratory fitness (VO) and reductions in HbA1c levels compared to MICT, indicating better glucose control. It is also time-efficient, requiring less total exercise time to achieve similar or better results than MICT.
Expected positive outcomes include improved visual acuity, contrast sensitivity, central visual field, and reduced diabetic retinopathy status among participants.
53% of participants using the FMD experienced improved glycaemic management compared to only 8% in the control group. The need for glucose-lowering medication significantly decreased in the FMD group.
The anticipated positive outcomes include improved diabetes self-management, better engagement with healthcare, and a reduction in health inequalities experienced by individuals with SMI. The intervention aims to empower patients through education and support, leading to enhanced health and wellbeing.
Identifying specific amino acids that are dysregulated in T2D could lead to targeted therapies that improve glucose management and reduce complications associated with the disease.
SGLT2is and GLP1-RAs were associated with a lower risk of 3-point MACE (myocardial infarction, stroke, death) compared to DPP4is and SUs, indicating better cardiovascular outcomes in patients with T2DM and CVD.
The study found that 44.6% of patients had acceptable glycemic control (HbA1c between 6% and 8%). However, a significant portion of patients (55.4%) exhibited poor glycemic control, indicating a need for improved management strategies.
All ketone supplements raised blood β-OHB levels, with the highest levels observed after ingestion of the ketone monoester. Blood glucose levels were similarly reduced across all supplements tested.
Effective glycaemic control and appropriate nutritional support are associated with improved patient outcomes, including reduced morbidity and mortality in critically ill patients.
AFO-202 significantly improved metabolic control of glucose, while both AFO-202 and N-163 improved immune parameters and lipid profiles. AFO-202 showed a decrease in HbA1C and glycated albumin, while N-163 improved lipid regulation and immunomodulation.
Fasting plasma glucose levels remained stable during and after walking, indicating that prolonged walking does not significantly alter fasting glucose measurements in individuals with type 2 diabetes.
The study aims to evaluate the feasibility of recruitment, retention, and data collection processes, as well as the acceptability of the DIAMONDS intervention and continuous glucose monitoring among participants.
The study found significant daily variation in blood glucose levels, with a peak in the morning and a trough at night, indicating that continuous enteral feeding does not eliminate the circadian influence on glucose metabolism in ICU patients.
SMBG was associated with lower rates of preeclampsia, reduced mean birthweight, fewer infants born large for gestational age, fewer cases of macrosomia, and lower rates of shoulder dystocia. Most end-users found SMBG convenient and beneficial for their health management.
The introduction of the new prioritization criteria and interactive dashboard led to a 60% reduction in the mean time spent by diabetes team members on patient reviews, resulting in a 147% increase in weekly clinic capacity. Patients who received remote reviews showed an 8.8 percentage point increase in time-in-range glucose levels compared to control patients after twelve months.
Almond consumption resulted in higher levels of unsaturated triglycerides and specific metabolites (aminomalonate, oxylipins) during the oGTT, indicating improved metabolic responses compared to cracker consumption.
The administration of canagliflozin resulted in significant changes in biomarkers: a decrease in fasting plasma glucose, a slight increase in serum creatinine, and a decrease in serum uric acid levels, indicating effective glycemic control and renal function impact.
The study found that among individuals with type 2 diabetes, 13.6% were prescribed GLP-1RAs and 11.5% SGLT2i, with one-year fill rates of approximately 52.5% for GLP-1RAs and 52.9% for SGLT2i, indicating some level of adherence to treatment.
MBSR significantly reduces fasting blood sugar levels and HbA1c in type 2 diabetes patients. It also improves psychological well-being, reducing symptoms of depression, anxiety, and enhancing emotional health.
Higher adherence to the Mediterranean diet was associated with lower cardiometabolic risk scores at both 16 and 34 weeks of gestation, indicating better health outcomes for both mother and child.
No significant differences in 24-hour and postprandial glucose concentrations were observed between the highest and lowest carbohydrate intake levels, indicating that modest changes in carbohydrate content do not influence glucose levels in T2D patients.
Identification of lifestyle factors that consistently associate with improved cardiometabolic traits, potentially guiding future health interventions.
The study found that individual postprandial CGM responses to duplicate meals were unreliable, indicating a need for more reliable methods for personalized dietary advice.
Higher fasting insulin levels are associated with increased odds of infertility in women, indicating a potential area for intervention.
SGLT2I users showed a significantly lower risk of myocardial infarction (HR: 0.34), cardiovascular mortality (HR: 0.53), and all-cause mortality (HR: 0.21) compared to DPP4I users, indicating a protective effect against major cardiovascular events.
The study found a statistically significant difference in the incidence of new-onset diabetes between the RY and OT groups, suggesting that RY reconstruction may be more effective in preventing postoperative diabetes in gastric cancer patients.
Bempedoic acid significantly lowered LDL-C, total cholesterol, non-HDL cholesterol, apolipoprotein B, and hsCRP in both MetS and non-MetS patients, with greater LDL-C reductions observed in patients with MetS. Additionally, it improved glycated hemoglobin and fasting plasma glucose levels specifically in patients with MetS.
Patients treated with SGLT2 inhibitors showed a significantly lower incidence of new onset cataracts (4.54% vs. 6.64%) and diabetic retinopathy (3.65% vs. 6.19%) compared to those treated with DPP4 inhibitors. The hazard ratios indicated a 33% lower risk for cataracts and a 43% lower risk for diabetic retinopathy in SGLT2I users.
SGLT2I use was associated with a significantly lower incidence of new-onset prostate cancer (60 cases) compared to DPP4I (102 cases), with a hazard ratio of 0.45, indicating a reduced risk after adjustments.
Patients using SGLT2I had significantly lower risks of myocardial infarction (HR: 2.91) and heart failure (HR: 2.49) compared to non-SGLT2I users, indicating a protective effect against these cardiovascular events.
The initiation of glucose-lowering drugs was associated with a reduction in the International Normalized Ratio (INR), indicating decreased warfarin efficacy, particularly among individuals with a significant decrease in HbA. Glycemic control improved during treatment, while inflammation remained low and unchanged.
Patients receiving SGLT2i showed a significantly thicker fibrous cap on unstable plaques, reduced lipid arc, and lower incidence of MACE and revascularization compared to those not receiving SGLT2i.
SGLT2I was associated with lower risks of new-onset NAFLD (HR: 0.39; 95% CI: 0.34-0.46) and HCC (HR: 0.46; 95% CI: 0.29-0.72) compared to DPP4I. Additionally, SGLT2I was linked to lower cancer-related mortality (HR: 0.29; 95% CI: 0.23-0.37) and all-cause mortality (HR: 0.28; 95% CI: 0.25-0.31).
Significant reduction in HbA1c levels in the treatment group compared to the placebo group, indicating improved blood glucose control. No negative impact on kidney or liver function was observed.